News | Artificial Intelligence | February 11, 2020

AI-assisted Radiologists Can Detect More Breast Cancer with Reduced False-positive Recall

A new study published in Lancet Digital Health shows a significant improvement in the performance of radiologists, before and after using AI

Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast

Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast. A small mass with micro-calcifications on the right-side breast was detected correctly by AI with an abnormality score of 96%. This case was recalled by 7 out of 14 radiologists (4 breast radiologists and 3 general radiologists) initially (without AI) and all 14 radiologists recalled this case correctly with the assistance of AI.

February 11, 2020 — A new study, published in Lancet Digital Health, shows the added value of AI-aided breast cancer detection from mammography images.

The study, conducted by Korean academic hospitals and Lunit, a medical AI company specializing in developing AI solutions for radiology and oncology, features large-scale data of over 170,000 mammogram examinations from five institutions across South Korea, USA and the UK, consisting of Asian and Caucasian female breast images. The dataset includes over 36,000 biopsy-proven, independent cancer positive cases — the largest scale of cancer data among mammography-related AI studies.

“It is an unprecedented quantity of data with accurate ground truth--especially the 36,000 cancer cases, which is seven times larger than the usual number of datasets from resembling studies conducted previously,” said Hyo-Eun Kim, the first author of the study and chief product officer at Lunit. “The quality of data has also been assured, with ethnic diversity, covering various imaging devices and scanning conditions. The marriage between the diversity of the dataset and the uniqueness of our algorithm, designed in interaction with one another, has been key to years of development of Lunit INSIGHT MMG since early 2016.”

The study shows a significant improvement in the performance of radiologists, before and after using AI. According to the study, the AI alone showed 88.8 percent sensitivity in breast cancer detection, whereas radiologists alone showed 75.3 percent. When radiologists were aided by AI, the accuracy increased by 9.5 percent to 84.8 percent.

One of the major findings also shows that AI, in comparison to the radiologists, displayed better sensitivity in detecting cancer with mass (90 percent vs 78 percent) and distortion or asymmetry (90 percent vs 50 percent). The AI was better in the detection of T1 cancers, which is categorized as early-stage invasive cancer. AI detected 91% of T1 cancers and 87% of node-negative cancers, whereas the radiologist reader group detected 74 percent for both.

Breast density is also an important factor in diagnosing mammograms, as dense breast tissues, mostly from the Asian population, are harder to interpret since dense tissue is more likely to mask cancers in mammograms. The findings show that the diagnostic performance of AI was less affected by breast density, whereas radiologists’ performance was prone to density, showing higher sensitivity for fatty breasts at 79.2 percent compared to dense breasts at 73.8 percent. When aided by AI, the radiologist’s sensitivity when interpreting dense breasts increased by 11 percent.

“One of the biggest problems in detecting malignant lesions from mammography images is that to reduce false negatives — missed cases — radiologists tend to increase recalls, casting a wider safety net, which brings an increased number of unnecessary biopsies,” said Eun-Kyung Kim, the corresponding author of the study and a breast radiologist at Yonsei University Severance Hospital. “It requires extensive experience to correctly interpret breast images, and our study showed that AI can help find more breast cancer with lesser recalls, also detecting cancers in its early stage of development.”

The study has been published online on 6 February 2020, in Lancet Digital Health. Lunit INSIGHT MMG is commercially available and is being used clinically, approved by Korea Ministry of Food and Drug Safety and pending approval by European CE within the first quarter and FDA clearance by later this year. It is available for free online demo at https://insight.lunit.io.

Related Content

Sponsored Content | Videos | Artificial Intelligence | February 21, 2020
In Artificial Intelligence at RSNA 2019, ITN Contributing Editor Greg Freiherr offers an overview of artificial intel
An example of the MRI scans showing long-term and short-term survival indications. #MRI

An example of the MRI scans showing long-term and short-term survival indications. Image courtesy of Case Western Reserve University

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — ...
Sponsored Content | Videos | Enterprise Imaging | February 19, 2020
Bill Lacy, vice president, Medical Informatics at FUJIFILM Medic...
Recognized as the “Pulitzer Prize of the business press,” the Jesse H. Neal Award finalists are selected for exhibiting journalistic enterprise, service to the industry and editorial craftsmanship
News | Radiology Business | February 19, 2020
February 19, 2020 — Connectiv, a division of The Software and Information Industry Association (SIIA), has announced
The Caption Guidance software uses artificial intelligence to guide users to get optimal cardiac ultrasound images in a point of care ultrasound (POCUS) setting.

The Caption Guidance software uses artificial intelligence to guide users to get optimal cardiac ultrasound images in a point of care ultrasound (POCUS) setting.

News | Artificial Intelligence | February 13, 2020
February 13, 2020 — The U.S.
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
PaxeraHealth enterprise imaging, PACS, VNA solutions
News | Enterprise Imaging | February 11, 2020
February 11, 2020 — Enterprise Imaging developer PaxeraHealth
An example of artificial intelligence (AI) being developed by Hitachi to automatically review and identify nodules on lung CT scans. This is part of a suite of AI apps Hitachi is developing. This example was being shown as a work in progress at RSNA 2019.

An example of artificial intelligence (AI) being developed by Hitachi to automatically review and identify nodules on lung CT scans. This is part of a suite of AI apps Hitachi is developing. This example was being shown as a work in progress at RSNA 2019. Photo by Dave Fornell.

Feature | Artificial Intelligence | February 07, 2020 | Sanjay Parekh, Ph.D. 
February 7, 2020 – At the 2019 Radiological Society...
Sponsored Content | Videos | Artificial Intelligence | February 07, 2020
At RSNA19, GE Healthcare introduced its...